In the BioHarmony Drug Report Database

"Preview" Icon

Fam-trastuzumab deruxtecan-nxki

Enhertu (trastuzumab deruxtecan) is an antibody pharmaceutical. Trastuzumab deruxtecan was first approved as Enhertu on 2019-12-20. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. It is known to target receptor tyrosine-protein kinase erbB-2.

 

Trade Name

 

Enhertu
 

Common Name

 

trastuzumab deruxtecan
 

ChEMBL ID

 

CHEMBL4297844
 

Indication

 

breast neoplasms, gastrointestinal neoplasms
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives)

Image (chem structure or protein)

Fam-trastuzumab deruxtecan-nxki structure rendering